Quality assessment | No of patients | Effect | Quality | ||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
No of studies | Design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Early vs. deferred androgen suppression therapy | Control | Relative(95% CI) | Absolute | |
Overall survival (follow-up median 6.5-11.9 years) | |||||||||||
3 | randomized trials | serious1,2,3 | no serious inconsistency | no serious indirectness | serious5,6,7,8 | none | 78/165 (47.3%) | 92/145 (63.4%) | HR 0.62 (0.46 to 0.84) | 170 fewer per 1000 (from 64 fewer to 264 fewer) | ⊕⊕ΟΟ low |
Cancer-specific survival (follow-up median 11.9 years) | |||||||||||
1 | randomized trials | serious1 | no serious inconsistency | no serious indirectness | Serious5,6 | none | 7/47 (14.9%) | 25/51 (49%) | HR 0.34 (0.18 to 0.64) | 285 fewer per 1000 (from 140 fewer to 376 fewer) | ⊕⊕ΟΟ low |
Clinical progression at 3 years (follow-up median 3-11.9 years) | |||||||||||
4 | randomized trials | serious1,2,3,4 | no serious inconsistency | no serious indirectness | serious5,6,7,8,9 | none | 13/187 (7%) | 44/171 (25.7%) | RR 0.29 (0.16 to 0.52) | 183 fewer per 1000 (from 124 fewer to 216 fewer) | ⊕⊕ΟΟ low |
Clinical progression at 9 years (follow-up median 6.5-11.9 years) | |||||||||||
3 | randomized trials | serious1,2,3 | no serious inconsistency | no serious indirectness | serious5,6,7,8 | none | 43/165 (26.1%) | 78/144 (54.2%) | RR 0.49 (0.36 to 0.67) | 276 fewer per 1000 (from 179 fewer to 347 fewer) | ⊕⊕ΟΟ low |